Last week, a 9-0 Supreme Court ruled that human genes do not count as patent-eligible subject matter but that fake genes with some DNA missing may. Ass'n for Molecular Pathology v. Myriad Genetics, Inc., No. 12-398, slip op. 12 (U.S. June 13, 2013) ("Groundbreaking, innovative, or even brilliant discovery does not by itself satisfy the §101 inquiry" on patentability. The Court warned that it might give a pass to "method" claims that relate to genes 

[Blawgletter's patent trial will likely end this week. So will the waiting for the gay marriage, affirmative action, and Voting Rights Act cases.]